ProtoKinetix in Partnership Discussions with Diabetes Specific Foundations and Research Organizations
ProtoKinetix in Partnership Discussions with Diabetes Specific Foundations and Research Organizations
Sep. 23, 2010 (Business Wire) -- ProtoKinetix Inc. (PKTX), over the last several weeks, has been in discussions with several diabetes specific organizations with a view to testing in 2-key areas in the treatment of diabetes. The company believes that AAGP™ will play a key role in potential treatment for Type 1 and Type 2 Diabetes.
Previous independently conducted in-vivo testing clearly demonstrated the importance of AAGP™ in islet cell transplantation. With recent developments from a variety of stem cell companies, the differentiation of stem cells into islets is, today, a reality. This success helps to overcome the limitations inherent in islet cell transplantations including the severe shortage of donor pancreases and the necessity for anti-rejection drugs when foreign islet cells are transplanted into recipients.
Both of these limitations have the potential to be eliminated with the development of successful differentiation of patient’s own stem cells. Testing to date has shown that the success of the transplant is dramatically improved by the addition of AAGP™ to the transplanted islet cells.
Type 1 Diabetes (Juvenile or early onset) is an auto-immune disease in which the insulin producing beta cells (islets) are destroyed by antibodies over time. Over the past few years, ProtoKinetix has tested a large variety of human cell lines under a wide range of hostile conditions. In every case, the cell lines that were treated with AAGP™ benefited from a significant extension of viable cell life.
The Company believes that AAGP™ has demonstrated the ability to provide a powerful layer of protection against the hostility of these auto-immune antibodies. Any postponement of the clinical symptoms of diabetes provides a major health benefit for diabetics. There is a strong potential for this molecule to play a pivotal part in the effective treatment of diabetes.
About ProtoKinetix
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.
For more detailed information, please visit our website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.
Ross L. Senior – President and CEO
Company Office:
Suite #1500 ProtoKinetix Inc.
2225 Folkestone Way
West Vancouver, BC V7S 2Y6
ProtoKinetix Inc.
Ross L. Senior, 604-926-6627
President and CEO
Source: Business Wire (September 23, 2010 - 7:00 AM EDT)
News by QuoteMedia
www.quotemedia.com
